[
  {
    "ts": null,
    "headline": "Top Stock Picks for Week of October 6, 2025",
    "summary": "A Strong Alternative Energy Stock and a Solid Drug Stock are in Focus.",
    "url": "https://finnhub.io/api/news?id=358c898fa96cec15e797140c1753207678235ee95b46dfe7457b8a448d7c7c70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759874460,
      "headline": "Top Stock Picks for Week of October 6, 2025",
      "id": 137007949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Strong Alternative Energy Stock and a Solid Drug Stock are in Focus.",
      "url": "https://finnhub.io/api/news?id=358c898fa96cec15e797140c1753207678235ee95b46dfe7457b8a448d7c7c70"
    }
  },
  {
    "ts": null,
    "headline": "Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly",
    "summary": "Dr. Peter Marks, the top Food and Drug Administration official whose forced resignation earlier this year set off a panic among biotech investors, is now an executive at  Eli Lilly  the company said on Tuesday.  Marks stepped down as the chief of the FDA’s Center for Biologics Evaluation and Research in March.  Lilly says he started work this month.",
    "url": "https://finnhub.io/api/news?id=3890c98a897fdd4de3d071058b5b8af7e181b9ef403719bfec098df3d4b0e8a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759871040,
      "headline": "Former Top FDA Official, Forced Out by Kennedy, Lands at Eli Lilly",
      "id": 137007950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Dr. Peter Marks, the top Food and Drug Administration official whose forced resignation earlier this year set off a panic among biotech investors, is now an executive at  Eli Lilly  the company said on Tuesday.  Marks stepped down as the chief of the FDA’s Center for Biologics Evaluation and Research in March.  Lilly says he started work this month.",
      "url": "https://finnhub.io/api/news?id=3890c98a897fdd4de3d071058b5b8af7e181b9ef403719bfec098df3d4b0e8a2"
    }
  },
  {
    "ts": null,
    "headline": "Acadia Healthcare Appoints Todd Young as Chief Financial Officer",
    "summary": "FRANKLIN, Tenn., October 07, 2025--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (\"Acadia\" or the \"Company\") today announced the appointment of Todd Young as Chief Financial Officer, effective October 27, 2025. Tim Sides, who has been serving as the Company’s interim CFO since August 2025, will resume his role as Senior Vice President, Operations Finance.",
    "url": "https://finnhub.io/api/news?id=a1f00526bcaa03f7e10b6ddfbcac92a1ec299589919017ea496c74ed77d94926",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759868100,
      "headline": "Acadia Healthcare Appoints Todd Young as Chief Financial Officer",
      "id": 137003160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FRANKLIN, Tenn., October 07, 2025--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (\"Acadia\" or the \"Company\") today announced the appointment of Todd Young as Chief Financial Officer, effective October 27, 2025. Tim Sides, who has been serving as the Company’s interim CFO since August 2025, will resume his role as Senior Vice President, Operations Finance.",
      "url": "https://finnhub.io/api/news?id=a1f00526bcaa03f7e10b6ddfbcac92a1ec299589919017ea496c74ed77d94926"
    }
  },
  {
    "ts": null,
    "headline": "Peter Marks, former top FDA vaccine official, joins Eli Lilly",
    "summary": "Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.",
    "url": "https://finnhub.io/api/news?id=9cefec46362a7d6a2c12d6b0ffeb701fb1f80d2ad103b11f921f3cd9b33401ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759854000,
      "headline": "Peter Marks, former top FDA vaccine official, joins Eli Lilly",
      "id": 137007952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.",
      "url": "https://finnhub.io/api/news?id=9cefec46362a7d6a2c12d6b0ffeb701fb1f80d2ad103b11f921f3cd9b33401ac"
    }
  },
  {
    "ts": null,
    "headline": "‘People are desperate’: how Mounjaro users are beating the price rise",
    "summary": "In January, when Sarah le Brocq signed up for a year’s supply of weight loss jab Mounjaro at £99 per month, it felt like a good deal. All the more so when it helped her to lose 7st in weight.",
    "url": "https://finnhub.io/api/news?id=a4c45352a9206f234a6e472941082c631d6a70fbeb8f1afc1ebeb0ee5028d2a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759845101,
      "headline": "‘People are desperate’: how Mounjaro users are beating the price rise",
      "id": 136998816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In January, when Sarah le Brocq signed up for a year’s supply of weight loss jab Mounjaro at £99 per month, it felt like a good deal. All the more so when it helped her to lose 7st in weight.",
      "url": "https://finnhub.io/api/news?id=a4c45352a9206f234a6e472941082c631d6a70fbeb8f1afc1ebeb0ee5028d2a6"
    }
  },
  {
    "ts": null,
    "headline": "Where Will LLY Be in 5 Years?",
    "summary": "After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.",
    "url": "https://finnhub.io/api/news?id=13508d20300668323bdbc59b38dfed199c8b154f3cff231ac87985b7cfc321d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759843994,
      "headline": "Where Will LLY Be in 5 Years?",
      "id": 136998817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.",
      "url": "https://finnhub.io/api/news?id=13508d20300668323bdbc59b38dfed199c8b154f3cff231ac87985b7cfc321d0"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=78b3cc1dd76971c66319805681b0721744be3ffbf15f41607d11ee24a1bf99fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759842004,
      "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
      "id": 136998818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=78b3cc1dd76971c66319805681b0721744be3ffbf15f41607d11ee24a1bf99fb"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=08fd7ed33475a858348a48d81a8662915a2067571b4b6be531b2476e884b588b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759842002,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 136998819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=08fd7ed33475a858348a48d81a8662915a2067571b4b6be531b2476e884b588b"
    }
  },
  {
    "ts": null,
    "headline": "Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy",
    "summary": "WALTHAM, Mass., October 07, 2025--Affinia Therapeutics (\"Affinia\"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced it has closed a $40 million Series C financing. The financing was led by New Enterprise Associates (NEA) with participation from new investor, Eli Lilly & Company, and existing investors Alexandria Venture Investments, LLC,",
    "url": "https://finnhub.io/api/news?id=6fa7517714b0369c15230ece64ded06c54f299ab7c68e27f6dd0063a7b1aa1a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759837500,
      "headline": "Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy",
      "id": 136998820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., October 07, 2025--Affinia Therapeutics (\"Affinia\"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced it has closed a $40 million Series C financing. The financing was led by New Enterprise Associates (NEA) with participation from new investor, Eli Lilly & Company, and existing investors Alexandria Venture Investments, LLC,",
      "url": "https://finnhub.io/api/news?id=6fa7517714b0369c15230ece64ded06c54f299ab7c68e27f6dd0063a7b1aa1a0"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and Leading Alzheimer's Disease Experts Call for Urgent Action to Close Diagnostic Gaps at Alzheimer Europe Conference",
    "summary": "Eli Lilly and Company, in partnership with leading Alzheimer's disease (AD) experts at this year's Alzheimer Europe Conference, have called for urgent improvements to diagnostic pathways to ensure people in Europe can benefit from new therapeutic innovation.",
    "url": "https://finnhub.io/api/news?id=8bf0676075553bafc4969ce78cbb997ae4082317eeabcf38a6d04ecb27e39dc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759834800,
      "headline": "Lilly and Leading Alzheimer's Disease Experts Call for Urgent Action to Close Diagnostic Gaps at Alzheimer Europe Conference",
      "id": 136998821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company, in partnership with leading Alzheimer's disease (AD) experts at this year's Alzheimer Europe Conference, have called for urgent improvements to diagnostic pathways to ensure people in Europe can benefit from new therapeutic innovation.",
      "url": "https://finnhub.io/api/news?id=8bf0676075553bafc4969ce78cbb997ae4082317eeabcf38a6d04ecb27e39dc5"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis",
    "summary": "New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC) achieve sustained, long-term outcomes through four years. The results were seen across multiple symptomatic, clinical, endoscopic, histologic and quality-of-life measures, including among patients who had previously failed a biologic or advanced therapy (27%). These data are the final results",
    "url": "https://finnhub.io/api/news?id=12c0a8a09c7778f64def163d011a146de2f1e9eec485262a03ab5f14284c826a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759833900,
      "headline": "Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis",
      "id": 136998822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC) achieve sustained, long-term outcomes through four years. The results were seen across multiple symptomatic, clinical, endoscopic, histologic and quality-of-life measures, including among patients who had previously failed a biologic or advanced therapy (27%). These data are the final results",
      "url": "https://finnhub.io/api/news?id=12c0a8a09c7778f64def163d011a146de2f1e9eec485262a03ab5f14284c826a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to invest more than $1B in India, Reuters reports",
    "summary": "Eli Lilly (LLY) plans to invest more than $1B in India in the coming years to boost manufacturing and supply through local drugmakers, Reuters’ Rishika Sadam reports. “We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, president of Lilly International, said, adding that India is a hub for capability building within its global network. Published first on TheFly – the ultimate source for real-time, market-moving breaking",
    "url": "https://finnhub.io/api/news?id=99fb49b7d343ba5ee9ff2d74f007303dae8f2afe9fd17a3e4051c00ee64acfea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759831555,
      "headline": "Eli Lilly to invest more than $1B in India, Reuters reports",
      "id": 136998823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) plans to invest more than $1B in India in the coming years to boost manufacturing and supply through local drugmakers, Reuters’ Rishika Sadam reports. “We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, president of Lilly International, said, adding that India is a hub for capability building within its global network. Published first on TheFly – the ultimate source for real-time, market-moving breaking",
      "url": "https://finnhub.io/api/news?id=99fb49b7d343ba5ee9ff2d74f007303dae8f2afe9fd17a3e4051c00ee64acfea"
    }
  },
  {
    "ts": null,
    "headline": "Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer",
    "summary": "Trump and Pfizer said they reached a landmark deal to cut drug prices. Most Americans won't see a benefit, but Pfizer will.",
    "url": "https://finnhub.io/api/news?id=113c9d7b7c6d7d5f0dffdcebf18a23fdf8b2763619c818a2a17a708c1f2bcab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759831200,
      "headline": "Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer",
      "id": 136998824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump and Pfizer said they reached a landmark deal to cut drug prices. Most Americans won't see a benefit, but Pfizer will.",
      "url": "https://finnhub.io/api/news?id=113c9d7b7c6d7d5f0dffdcebf18a23fdf8b2763619c818a2a17a708c1f2bcab0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk cuts hit production line jobs at key US plant, posts show",
    "summary": "STORY: Novo Nordisk has laid off dozens of employees in the U.S.That's what Reuters has seen in a review of LinkedIn posts.The Wegovy-maker made the cuts at the largest U.S. manufacturing site for its popular obesity and diabetes drugs.Its a signal of where the firm is making cuts in a major restructuring under new CEO Mike Doustdar.The layoffs are a small part of a planned 9,000 job removals globally.The Danish giant wants to sharpen its focus, trim costs, and regain lost ground in competition with U.S. rival Eli Lilly.The cuts also come as President Trump's administration pressures pharmaceutical companies to expand U.S. drug production and create more domestic jobs.Novo last year became Europe's most valuable listed company on demand for weight-loss drugs.But it has since had a sharp share price slide as sales growth slowed.Its now trying to reduce costs and staff that grew as it rode the Wegovy boom.A Novo spokesperson declined a Reuters request for further details beyond last month's global layoffs announcement.",
    "url": "https://finnhub.io/api/news?id=fee50aacab4625d8378ea85608dc2e9ae8aff1e0a332f12e8686d9814972d2c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759830790,
      "headline": "Novo Nordisk cuts hit production line jobs at key US plant, posts show",
      "id": 136998825,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk has laid off dozens of employees in the U.S.That's what Reuters has seen in a review of LinkedIn posts.The Wegovy-maker made the cuts at the largest U.S. manufacturing site for its popular obesity and diabetes drugs.Its a signal of where the firm is making cuts in a major restructuring under new CEO Mike Doustdar.The layoffs are a small part of a planned 9,000 job removals globally.The Danish giant wants to sharpen its focus, trim costs, and regain lost ground in competition with U.S. rival Eli Lilly.The cuts also come as President Trump's administration pressures pharmaceutical companies to expand U.S. drug production and create more domestic jobs.Novo last year became Europe's most valuable listed company on demand for weight-loss drugs.But it has since had a sharp share price slide as sales growth slowed.Its now trying to reduce costs and staff that grew as it rode the Wegovy boom.A Novo spokesperson declined a Reuters request for further details beyond last month's global layoffs announcement.",
      "url": "https://finnhub.io/api/news?id=fee50aacab4625d8378ea85608dc2e9ae8aff1e0a332f12e8686d9814972d2c5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly plans major $1bn expansion in Telangana, India",
    "summary": "Eli Lilly will establish new contract manufacturing facilities and a manufacturing and quality hub in Hyderabad.",
    "url": "https://finnhub.io/api/news?id=16c070cf394af546df635b59e9ed5bf0f11757fcb96240271c9406ab06ec9f50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759827039,
      "headline": "Eli Lilly plans major $1bn expansion in Telangana, India",
      "id": 136998826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly will establish new contract manufacturing facilities and a manufacturing and quality hub in Hyderabad.",
      "url": "https://finnhub.io/api/news?id=16c070cf394af546df635b59e9ed5bf0f11757fcb96240271c9406ab06ec9f50"
    }
  },
  {
    "ts": null,
    "headline": "New positive data for Eli Lilly's Omvoh",
    "summary": "Eli Lilly reports new data showing that Omvoh is the first and only interleukin-23p19 to help patients with moderate-to-severe active ulcerative colitis achieve long-term sustained results for four...",
    "url": "https://finnhub.io/api/news?id=6fb192d56842a4f3c0d569c18f8af2b2d0ff00ddf2e8438314f26ecc2ddd1d8c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759826432,
      "headline": "New positive data for Eli Lilly's Omvoh",
      "id": 136998071,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly reports new data showing that Omvoh is the first and only interleukin-23p19 to help patients with moderate-to-severe active ulcerative colitis achieve long-term sustained results for four...",
      "url": "https://finnhub.io/api/news?id=6fb192d56842a4f3c0d569c18f8af2b2d0ff00ddf2e8438314f26ecc2ddd1d8c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds",
    "summary": "Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. See why NVO stock is a Buy now.",
    "url": "https://finnhub.io/api/news?id=6525c8451feaf7d3f3b5391f7effdd3fd219b4627e2a7181944a193a36ffcd4c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759817684,
      "headline": "Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds",
      "id": 136997675,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187492839/image_2187492839.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. See why NVO stock is a Buy now.",
      "url": "https://finnhub.io/api/news?id=6525c8451feaf7d3f3b5391f7effdd3fd219b4627e2a7181944a193a36ffcd4c"
    }
  },
  {
    "ts": null,
    "headline": "Epsilogen Announces the Appointment of Cristina Oliva, MD, PhD as Chief Medical Officer",
    "summary": "LONDON, October 07, 2025--Epsilogen, the world’s leading pan-isotype antibody therapeutic company for the treatment of cancer, today announces the appointment of Cristina Oliva, MD, PhD, as Chief Medical Officer. Dr. Oliva is a Board-certified oncologist and brings global experience across all stages of oncology drug development.",
    "url": "https://finnhub.io/api/news?id=20a7c1512afa25eaa3fbcec6364b9dc3fe475044933e8d93881c319f6de13058",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759816800,
      "headline": "Epsilogen Announces the Appointment of Cristina Oliva, MD, PhD as Chief Medical Officer",
      "id": 136998827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON, October 07, 2025--Epsilogen, the world’s leading pan-isotype antibody therapeutic company for the treatment of cancer, today announces the appointment of Cristina Oliva, MD, PhD, as Chief Medical Officer. Dr. Oliva is a Board-certified oncologist and brings global experience across all stages of oncology drug development.",
      "url": "https://finnhub.io/api/news?id=20a7c1512afa25eaa3fbcec6364b9dc3fe475044933e8d93881c319f6de13058"
    }
  }
]